Powdered cellulose
Powdered cellulose is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cellulose sodium phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CALCIBIND | Mission Pharmacal | N-018757 DISCN | 1982-12-28 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bio skin crystal bio-cellulose mask | OTC monograph final | 2015-09-23 |
| complete eye relief | C200263 | 2026-03-05 |
| family care single use lubricant eye drop 0.4ml 30ct | C200263 | 2026-01-16 |
| irritated eye relief | C200263 | 2026-03-05 |
| limulus bio cellulose mask | unapproved drug other | 2017-06-28 |
| miracle of skin | unapproved drug other | 2018-03-23 |
| optase allegro | C200263 | 2026-01-27 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1521 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 35 | 9 | 3 | 2 | 62 | 106 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 13 | 3 | 8 | 32 | 59 |
| Inflammation | D007249 | MP_0001845 | — | 5 | 7 | 2 | 2 | 30 | 45 |
| Overweight | D050177 | — | E66.3 | 2 | 5 | 3 | 1 | 35 | 45 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 5 | 11 | 4 | 6 | 14 | 39 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 5 | 15 | 5 | 2 | 13 | 37 |
| Infections | D007239 | EFO_0000544 | — | 3 | 9 | 4 | 3 | 13 | 32 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 4 | 7 | 3 | 2 | 17 | 32 |
| Syndrome | D013577 | — | — | 1 | 10 | 4 | 4 | 16 | 32 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 2 | 1 | — | 2 | 24 | 28 |
Show 171 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 4 | 13 | 7 | — | 4 | 23 |
| Communicable diseases | D003141 | — | — | 1 | 6 | 1 | — | 10 | 18 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 5 | 6 | 2 | — | 4 | 15 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | 1 | 2 | 1 | — | 12 | 15 |
| Cognition | D003071 | EFO_0003925 | — | — | 1 | 2 | — | 13 | 15 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 6 | 4 | 4 | — | — | 14 |
| Sleep | D012890 | GO_0030431 | — | — | 2 | 3 | — | 9 | 13 |
| Fatty liver | D005234 | EFO_0003934 | — | 3 | 5 | 2 | — | 5 | 13 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 3 | 3 | — | 7 | 12 |
| Respiratory tract infections | D012141 | — | J06.9 | — | 2 | 3 | — | 7 | 12 |
Show 140 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | D005221 | — | R53.83 | 2 | 5 | — | — | 20 | 25 |
| Oxidative stress | D018384 | EFO_1001905 | — | 3 | 3 | — | — | 10 | 14 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 6 | 5 | — | — | 3 | 11 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 3 | 6 | — | — | 3 | 10 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 3 | — | — | 7 | 10 |
| Healthy aging | D000073656 | — | — | 1 | 1 | — | — | 8 | 10 |
| Gastrointestinal microbiome | D000069196 | — | — | 4 | 2 | — | — | 6 | 10 |
| Probiotics | D019936 | — | — | 1 | 1 | — | — | 6 | 8 |
| Cocaine-related disorders | D019970 | — | F14 | 2 | 7 | — | — | — | 8 |
| Sclerosis | D012598 | — | — | 1 | 6 | — | — | 1 | 7 |
Show 191 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | 1 | — | — | — | 14 | 15 |
| Pharmacokinetics | D010599 | — | — | 6 | — | — | — | — | 6 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | 4 | 5 |
| Autism spectrum disorder | D000067877 | — | F84.0 | 1 | — | — | — | 4 | 5 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 3 | — | — | — | 2 | 5 |
| Parasomnias | D020447 | — | G47.5 | 1 | — | — | — | 4 | 5 |
| Goiter | D006042 | EFO_0004283 | E04.9 | 1 | — | — | — | 3 | 4 |
| Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | 2 | 3 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | 2 | — | — | — | 1 | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 2 | — | — | — | 1 | 3 |
Show 51 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Affect | D000339 | — | — | — | — | — | — | 10 | 10 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 9 | 9 |
| Psychological stress | D013315 | — | — | — | — | — | — | 5 | 5 |
| Mental fatigue | D005222 | — | — | — | — | — | — | 5 | 5 |
| Psychological well-being | D000092862 | — | — | — | — | — | — | 5 | 5 |
| Surgical wound | D000072836 | — | — | — | — | — | — | 4 | 4 |
| Alopecia | D000505 | — | L64 | — | — | — | — | 4 | 4 |
| Healthy diet | D000072001 | — | — | — | — | — | — | 4 | 4 |
| Postmenopause | D017698 | — | — | — | — | — | — | 3 | 3 |
| Placebos | D010919 | — | — | — | — | — | — | 3 | 3 |
Show 218 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Powdered cellulose |
| INN | _ |
| Description | Lacrisert (microcrystalline cellulose) is an insert placed in the eye to treat moderate to severe dry eyes. It also can be used to treat the following eye conditions: exposure keratitis, decreased corneal sensitivity and recurrent corneal erosions. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297557 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | ZY7ZTE7LFH (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Powdered cellulose
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,722 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use